“Akt–the Mammalian Target of Rapamycin (mTOR) Pathway Inhibition Increases Cervical Cancer Cell Chemosensitivity to Active Form of Irinotecan (SN-38)”, IJIHS, vol. 1, no. 1, pp. 13–21, Sep. 2013, Accessed: Jul. 18, 2026. Available: https://journal.fk.unpad.ac.id/index.php/ijihs/article/view/103